Lupus tumidus
ICD-10 L93 · ICD-11 EB51.Y.1

Lupus Tumidus Without Severe CLE Lesions: Treatment After Mycophenolate Mofetil Has Not Achieved Adequate Disease Control

This protocol applies to patients with lupus tumidus presenting in the absence of severe or disseminated cutaneous lupus erythematosus (CLE) skin lesions, where the preceding systemic treatment line has not achieved the expected improvement in CLE disease activity.

Clinical scenario Lupus tumidus occurring without severe or disseminated cutaneous LE skin lesions. Disease activity has remained inadequately controlled despite a prior course of systemic therapy evaluated over the recommended timeframe.
Previous treatment — insufficient response The prior treatment line used mycophenolate mofetil or mycophenolic acid, preferably in combination with antimalarial drugs. The target — improvement of cutaneous lupus erythematosus disease activity after 3–6 months of treatment — was not achieved. This unmet goal is the trigger for escalation to the current protocol.
Treatment goal Improvement of cutaneous lupus erythematosus disease activity, evaluated after a minimum of 3 and a maximum of 6 months of treatment.
Next-line approach — partial overview Following failure of the previous line, a range of further systemic agents may be considered, preferably in combination with antimalarial drugs. The complete structured regimen — including agent selection, decision criteria, and sequencing — is available in the full protocol.
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14491

  1. Thalidomide may be considered in selected cases of refractory CLE lesions, preferably in combination with antimalarial drugs.
  2. In one case report and two open label studies, the majority of patients (> 80 %) with treatment refractory SCLE, CCLE, and other subtypes showed a response after only two weeks of oral lenalidomide dosed at 5–10 mg/day.
  3. Belimumab may be considered for CLE treatment.
  4. Rituximab may be considered for CLE treatment.
  5. IVIG may be considered for treatment of CLE.
  6. Azathioprine may be considered for treating CLE.
  7. Ciclosporin may be considered for treating CLE.
  8. It is recommended to evaluate the efficacy of systemic treatment for CLE after a minimum of three months and a maximum of six months (except for glucocorticoids).
View source ↗